• Overview
  • Eligibility
  • More info
  • Locations

Phase II Study of Theophylline in Chronic Lymphocytic Leukemia (NCT00003808)

National Cancer Institute (NCI)
North Central Cancer Treatment Group
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of theophylline in treating patients who have in situ, stage I, or stage II chronic lymphocytic leukemia.
  • Drug: theophylline
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    OBJECTIVES: I. Determine the response rate in asymptomatic patients with stage 0, I, or II B-cell chronic lymphocytic leukemia treated with theophylline. II. Determine the toxicity of this treatment in these patients.

    OUTLINE: Patients receive oral theophylline daily. Daily treatment continues for a maximum of 6 months in the absence of disease progression or unacceptable toxicity. Patients are followed every 4 months for 1 year.

    PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study over approximately 10 months.

    71 locations

    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 April, 1999
    Updated:
    21 August, 2013
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!